News & Updates
Showing Pharmacy articles
Showing
Intensive urate lowering of little benefit to patients with erosive gout
A more intensive serum urate-lowering therapy falls short of improving bone erosion scores in patients with erosive gout, in addition to being associated with a high treatment burden, as shown in a study.
Novel drug promising for paediatric Tourette syndrome
The experimental drug ecopipam helps minimize motor and phonic tics in children and adolescents with Tourette syndrome, in addition to being safe and well tolerated, according to the results of a phase 2b trial presented at the 2022 American Academy of Neurology’s Annual Meeting (AAN 2022).
Ofatumumab boasts long-term safety in relapsing multiple sclerosis
Treatment with ofatumumab in the long term (approximately 3.5 years) among patients with relapsing multiple sclerosis (MS) is well-tolerated, with no new safety risks found, according to the results of ALITHIOS, presented at the 2022 Annual Meeting of the American Academy of Neurology.
Ramucirumab–paclitaxel combo works better against HER2-positive vs -negative gastric cancers
Treatment with the combination of ramucirumab and paclitaxel in the second-line setting appears to yield higher responses among patients with HER2-positive gastric or gastro-oesophageal junction adenocarcinoma than among those with HER2-negative disease, according to a subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
